Lichen International Prices $3.5M Unit Offering at $0.20; Shares Fall 86%
Lichen International (LICN) filed a 424B5 on Nov. 10, 2026, for a $3.5 million unit offering priced at $0.20 per unit, with each unit consisting of one Class A ordinary share or pre-funded warrant plus one ordinary warrant.
What happened
Lichen International Limited (Nasdaq: LICN), a Cayman Islands holding company whose operations are conducted through subsidiaries in China, filed a prospectus supplement on Nov. 10, 2026, covering an offering of 17,500,000 units at a combined offering price of US$0.20 per unit, according to the 424B5 filing.
Each unit consists of one Class A ordinary share, or one pre-funded warrant in lieu of a share, together with one ordinary warrant. The company said the offering represents US$3,500,000 of aggregate gross proceeds, assuming all initial shares or pre-funded warrant equivalents are issued as shares or exercised for cash.
The filing states the last reported sale price of the Class A ordinary shares on Nasdaq was $0.4911 on Nov. 9, 2026, the day before the filing. The stock closed at $0.042 on the event date, down 86.23% from the previous close of $0.305, on volume of 60,847,700 shares versus an average volume of 35,858, according to the price data.
Univest Securities, LLC acted as sole placement agent on a "reasonable best efforts" basis. The filing does not state a reason for the offering or for the share price decline.
The company
Lichen International is a Cayman Islands exempted company with limited liability. The filing states the company is not a Chinese operating company: it is a holding company with no material operations of its own, and its business is conducted through subsidiaries organized in the People's Republic of China.
The filing says the company does not use a variable interest entity (VIE) structure. Investors in the offering acquire securities of the Cayman Islands holding company, not direct equity interests in the PRC operating entities, the filing states.
The company was formerly known as Lichen China Limited. Its Class A ordinary shares trade on the Nasdaq Capital Market under the symbol LICN.
What this means
A 424B5 is a prospectus supplement filed under Rule 424(b)(5) of the Securities Act. It is used when a company sells securities off an already-effective shelf registration statement, which lets it raise capital without filing a full new registration each time. The filing references Registration No. 333-291878 and a base prospectus dated Dec. 10, 2025.
The instruments here are more complex than plain shares. A pre-funded warrant is a security that is sold for almost the full share price (here US$0.19, versus US$0.20 for the unit) and carries a remaining exercise price of US$0.01; it lets an investor effectively buy a share while deferring a small part of the payment. An ordinary warrant is the right to buy a share later at a set price — in this case US$0.20 — and is a common sweetener in small-cap financings.
The ordinary warrants also carry an alternative. Rather than paying US$0.20 per share in cash, a holder may elect a "zero-price exercise" and receive 4.72 Class A ordinary shares for each ordinary warrant, without paying additional consideration, subject to ownership limits and adjustment. The filing says the offering covers up to 82,600,000 shares underlying the ordinary warrants assuming all are exercised using that 4.72-fold alternative, for 100,100,000 aggregate underlying shares, excluding any overallotment.
That structure matters because it means the offering can result in far more shares being issued than the 17,500,000 units sold initially. The filing notes the underlying shares are not all issued at closing. Dilution from warrant exercises is a known feature of this kind of unit offering, and the filing does not quantify its effect.
As a foreign private issuer listed in the U.S., Lichen International is also subject to China Securities Regulatory Commission (CSRC) filing requirements. The filing states the company must file with the CSRC within three business days after completing offerings under this registration statement and that it will prepare the required report. It also states that, after consulting PRC counsel Tianyuan Law Firm, no PRC laws currently require permission from PRC authorities to issue securities to foreign investors, and that it has not received any inquiry, notice, warning, sanction, or regulatory objection to the offering from the CSRC, the CAC, or other PRC authorities.
Sources
- Daily price and volume history
- 424B5 filed 2026-11-10
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.